RSV qRT-PCR
The RSV qRT-PCR test is intended for the quantitative detection of respiratory syncytial virus.
About RSV
Human respiratory syncytial virus (RSV), a negative-sense, single-stranded RNA virus, causes a variety of respiratory illnesses. In at risk infants and children, it can cause bronchitis, croup, and lower respiratory infections like bronchiolitis and pneumonia. Premature infants, very young infants, and those with chronic (always present) lung or heart disease or with suppressed (weakened) immune systems have a greater chance of having a more severe infection such as a lower respiratory tract infection. Symptomatic RSV infections may occur in adults, particularly in healthcare workers or caretakers of small children. High-risk adults, such as those with certain chronic illnesses or immunosuppression, may have more severe symptoms consistent with a lower respiratory tract infection, such as pneumonia.
ProcedureExtraction of RSV nucleic acid from specimen, followed by combined reverse transcription of viral RNA and PCR amplification using real-time reverse transcriptase PCR (RT-PCR) methods. An internal control is added to ensure that extraction was performed correctly and that the RT-PCR reaction was not inhibited.
This test was developed and its performance characteristics determined by Eurofins Viracor. It has not been cleared or approved by the U.S. Food and Drug Administration. Results should be used in conjunction with clinical findings, and should not form the sole basis for a diagnosis or treatment decision.
SpecificityThe primers and probes used in the RSV assays are specific for known RSVA and RSVB strains. Additionally, no cross reactivity was detected when tested against ADV, CMV, EBV, HSV-1, HSV-2, Enterovirus, Coronavirus 229E, SARS CoV-2, Rhinovirus, Influenza H1N1 2009 Pandemic, Influenza H1N1 Seasonal, Influenza H3N2, Influenza B, C. pneumoniae and Group A Strep. In silico analysis has demonstrated that Viracor’s RSV assays are not expected to cross-react with other respiratory viruses, bacteria or fungal pathogens/commensals. This assay does not differentiate between RSVA or RSVB.
Same day (within 24 hours from receipt of specimen), Monday through Friday.
Specimen Type | Test Code | CPT Code | NY Approved | Volume | Assay Range | Special Instructions |
---|---|---|---|---|---|---|
nasal swab [Quant] | 7178 | 87634 | No | 2 mL |
459 - 1.00E+09 copies/mL |
|
NP swab [Quant] | 7178 | 87634 | No | 2 mL |
459 - 1.00E+09 copies/mL |
|
BAL [Quant] | 7179 | 87634 | No | 2 mL |
579 - 1.00E+09 copies/mL |
|
bronch wash [Quant] | 7179 | 87634 | No | 2 mL |
579 - 1.00E+09 copies/mL |
|
nasal swab [Qual] | 7180 | 87634 | No | 2 mL |
Detected / Not Detected |
|
NP swab [Qual] | 7180 | 87634 | No | 2 mL |
Detected / Not Detected |
|
BAL [Qual] | 7181 | 87634 | No | 2 mL |
Detected / Not Detected |
|
bronch wash [Qual] | 7181 | 87634 | No | 2 mL |
Detected / Not Detected |
|
Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with patient's name and collection date. A Eurofins Viracor test requisition form must accompany each specimen. For additional testing, please send a separate specimen. Refer to our website for accepted specimen types. Ship specimens FedEx Priority Overnight® to: Eurofins Viracor, 18000 W 99th St. Ste, #10, Lenexa, KS 66219.
Causes for RejectionDry swab, wood shafted swab, calcium alginate swab, specimens received in trap containers, specimens beyond their acceptable length of time from collection as listed in the specimen handling, or specimen types other than those listed.
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Eurofins Viracor's interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Eurofins Viracor assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
We will continue to follow federal and state requirements for both notification of results and any confirmatory testing that is required by another agency.